Jie Xu

Dr. Jie Xu


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
HYHan Yao
Han Yao
JLJiang Lan
Jiang Lan
CLChushu Li
Chushu Li
Hubing ShiHubing Shi
Hubing Shi
JBJean-Philippe Brosseau
Jean-Philippe Brosseau
JXJie Xu
Jie Xu

18 March 2020
Verified
Book Chapter
Closed access
PDF file
LALuoyan Ai
Luoyan Ai
AXAntao Xu
Antao Xu
JXJie Xu
Jie Xu

27 March 2011 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JXJie Xu
Jie Xu
JRJoke Reumers
Joke Reumers
JCJosé R Couceiro
José R Couceiro
Frederik De SmetFrederik De Smet
Frederik De Smet
RGRodrigo Gallardo
Rodrigo Gallardo
Joost SchymkowitzJoost Schymkowitz
Joost Schymkowitz

5 November 2018 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
HWHuanbin Wang
Huanbin Wang
HYHan Yao
Han Yao
CLChushu Li
Chushu Li
Hubing ShiHubing Shi
Hubing Shi
JLJiang Lan
Jiang Lan
JXJie Xu
Jie Xu

18 March 2020
Verified
Book Chapter
Closed access
PDF file
SCSamya Van Coillie
Samya Van Coillie
BWBartosz Wiernicki
Bartosz Wiernicki
JXJie Xu
Jie Xu

30 November 2014 in Cancer Research
Verified
Journal Article
Open access
PDF file
YHYe Hu
Ye Hu
JWJilin Wang
Jilin Wang
JQJin Qian
Jin Qian
XKXuan Kong
Xuan Kong
JTJieting Tang
Jieting Tang
JFJing-Yuan Fang
Jing-Yuan Fang
It is increasingly evident that long noncoding RNAs (lncRNA) have causative roles in carcinogenesis. In this study, we report findings implicating a novel lncRNA in gastric cancer, termed GAPLINC (gastric adenocarcinoma predictive long intergenic noncoding RNA), based on the use of global microarray and in situ hybridization (ISH) analyses to identify aberrantly expressed lncRNA in human gastric cancer specimens. GAPLINC is a 924-bp-long lncRNA that is highly expressed in gastric cancer tissues. GAPLINC suppression and with gene expression profiling in gastric cancer cells revealed alterations in cell migration pathways, with CD44 expression the most highly correlated. Manipulating GAPLINC expression altered CD44 mRNA abundance and the effects of GAPLINC on cell migration and proliferation were neutralized by suppressing CD44 expression. Mechanistic investigations revealed that GAPLINC regulates CD44 as a molecular decoy for miR211-3p, a microRNA that targets both CD44 and GAPLINC. Tissue ISH analysis suggested that GAPLINC overexpression defines a subgroup of patients with gastric cancer with very poor survival. Taken together, our results identify a noncoding regulatory pathway for the CD44 oncogene, shedding new light on the basis for gastric cancer cell invasiveness. Cancer Res; 74(23); 6890–902. ©2014 AACR.